Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine discusses how technology can be used to improve the way we gather and use real-world evidence, the promise that real-world evidence holds, and how he thinks real-world evidence will be used in the coming years.
This page contains sponsored advertising
Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine discusses how technology can be used to improve the way we gather and use real-world evidence, the promise that real-world evidence holds, and how he thinks real-world evidence will be used in the coming years.
Transcript
How can technology be used to improve the way we gather and use real-world evidence?
There’s a lot of technology around us every day, from our phones to our watches, to get our information that we can leverage that’s outside of a health system. So, if you think about that, we’re trying to get to a fuller picture of what’s happening to a person, to a group of people, regarding their journey in health, and so technology is a great enabler for that and something we can take advantage of for real-world evidence.
What promise does the use of real-world evidence hold? How can and should it be used to improve care?
Everyday people want to understand, “what do they need today?” Clinicians try to understand what should they actually offer to a patient. People try and understand what health decisions they should make in a better way among the many choices that they have. So, if you think about real-world evidence, that’s actually incorporating both of those concepts in terms of what a clinician can offer a patient, what a patient decides in terms of the alternatives that they have, and then actually hopefully learning from that experience, so that others down the road can make better decisions.
As technology continues to evolve, what is your projection for how it will be used 5 years from now to improve the use of real-world evidence in a way that it currently isn’t being used?
In some ways the question is not just 5 years, but what will happen a year from now, or 3 years from now. Certainly, with the advances in terms of having greater access to data, the ease of computational methods, and the better way to incorporate various data silos that hadn’t been done before, the technologies can really transform what can be used in 3 or 5 years. Seeing how the ecosystem changes from individuals having greater access to information that might have empowered them for better decisions to clinicians or systems empowered to make better decisions for access to data to also regulators and payers, for instance, actually using real-world data to drive their decisions, and technology is going to be the great enabler for all of that.
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference for Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, has been made in the fight against the HIV pandemic given the current political climate.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More